GLP-1 Treatment in Minnesota: What It Costs and Who Covers It

A Minnesota overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.

Just under a third of Minnesota adults — 32.3% — have obesity, according to the CDC's 2024 Behavioral Risk Factor Surveillance System survey of 13,528 residents. Add in adults classified as overweight and the number climbs to 67.8% of the state's adult population. Minnesota's rate has actually eased slightly over the past few years — from 33.6% in 2022 to 33.3% in 2023 to 32.3% in 2024 — though it's still above the 30.7% and 32.4% recorded in 2020 and 2021. A related figure: 17.5% of Minnesota adults report no leisure-time physical activity at all 2.

Minnesota's population was 5,793,151 in the Vintage 2024 estimates — the 22nd most populous state, up roughly 40,100 residents (+0.70%) in 2024 alone 3.

Adult obesity rate (2024)
32.3%2
National adult obesity rate
Not published for this area. We do not estimate it.
Adults with obesity (modelled)
Not published for this area. We do not estimate it.
State population
5,793,1513
Uninsured rate
Not published for this area. We do not estimate it.
Median household income
Not published for this area. We do not estimate it.
Medicaid coverage for weight loss
Minnesota Medical Assistance (Minnesota Health Care Programs / MHCP) covers Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) for obesity, subject to fee-for-service prior authorization. Criteria: BMI ≥30 (adults, no comorbidity required) or ≥27 with a weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia); ages 12–17 qualify at BMI ≥30 plus body weight >60kg; documented reduced-calorie diet or RD care; documented increased physical activity unless contraindicated; no disqualifying contraindications; no concurrent use of another weight-loss drug. Initial approval: 6 months for Wegovy/Saxenda/Contrave/Xenical-orlistat (renewable) or 3 months for phentermine-class drugs (not renewable). Renewal requires ≥5% weight loss (or ≥5% BMI reduction for the 12–17 cohort), then 12-month renewal increments; continued-maintenance documentation required beyond 18 months.5

Does Minnesota Medicaid cover GLP-1s?

Yes — with conditions. Minnesota Medical Assistance, administered through Minnesota Health Care Programs (MHCP), covers Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) for obesity, subject to fee-for-service prior authorization 56.

To qualify: a BMI of 30 or higher with no comorbidity required, or 27+ with a weight-related condition such as hypertension, type 2 diabetes, or high cholesterol (12–17 year-olds qualify at BMI 30+ plus body weight over 60kg); documented diet counseling or registered-dietitian care; documented increased physical activity unless medically excused; and no contraindications or concurrent use of another weight-loss drug. Initial approval lasts six months for Wegovy, Saxenda, and two non-GLP-1 options (renewable), or three months for phentermine-class stimulants (not renewable). Renewing requires documented weight loss of at least 5%, after which coverage continues in 12-month increments, with extra documentation required past 18 months 56.

Minnesota's own criteria page was substantially rewritten sometime between mid-July and August 21, 2026 — recent enough that it's worth confirming any single detail directly with MHCP before relying on it 67.

What GLP-1 care costs through Astra

Astra's pricing doesn't change by state. Every patient — in Minneapolis, in Rochester, or in a small town hours from the nearest specialist — pays $68/month for semaglutide or $118/month for tirzepatide, billed on a 12-month plan ($816 and $1,416 paid annually). There's no Minnesota markup and no Minnesota discount.

Telehealth rules and access in Minnesota

Physicians prescribing GLP-1s to Minnesota patients — in person or via telehealth — are licensed and overseen by the Minnesota Board of Medical Practice. The board's specific current guidance on telehealth prescribing of anti-obesity medications is still being confirmed for this page — check with the board directly for the latest rules 9.

What's certain: Astra is licensed to treat patients in all 50 states, Minnesota included. A patient in Bemidji or International Falls gets the identical consult, prescription, and price as a patient in downtown Minneapolis.

GLP-1 care in Minneapolis

Minnesota's largest city has its own page in progress covering local obesity data, clinic pricing, and specialist access.

Astra treats patients in Minnesota through state-licensed physicians.

Cities in Minnesota

Frequently asked questions

Does Minnesota Medicaid cover GLP-1 medications like Wegovy or Zepbound for weight loss?

Yes. Minnesota Medical Assistance (MHCP) covers Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) for obesity, subject to fee-for-service prior authorization. Qualifying generally means a BMI of 30+ (or 27+ with a related condition like high blood pressure or type 2 diabetes), documented diet and activity efforts, and no disqualifying contraindications. Initial approval runs 3–6 months, and continuing coverage requires documented weight loss of at least 5%. DHS revised this policy between mid-July and August 21, 2026, so confirm current specifics with your MHCP plan or provider.

How much does Astra cost for patients in Minnesota?

The same as everywhere Astra operates: $68/month for semaglutide or $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually). There's no Minnesota-specific price.

Is Astra cheaper in Minnesota than other options?

It depends what you're comparing it to, not where you live — Astra's price is identical for a patient in Minneapolis and a patient in a rural county three hours away. Whether that beats a specific Minnesota clinic's cash price or a Medicaid-covered prescription depends on that option's cost and your coverage, not your location.

I don't live near Minneapolis or St. Paul — can I still use Astra?

Yes. Astra is licensed to treat patients in all 50 states through telehealth, so residents anywhere in Minnesota get the same access and the same price as patients in the Twin Cities.

What are Minnesota's telehealth rules for prescribing GLP-1 medications?

Prescribing is overseen by the Minnesota Board of Medical Practice under the state's telehealth practice standards. The board's specific current guidance on telehealth prescribing of anti-obesity medications is still being confirmed for this page — check directly with the board for the latest rules.

Sources

  1. CDC — Nutrition, Physical Activity, and Obesity: BRFSS dataset — https://data.cdc.gov/Nutrition-Physical-Activity-and-Obesity/Nutrition-Physical-Activity-and-Obesity-Behaviora/hn4x-zwk7
  2. CDC BRFSS Socrata API query — Minnesota adult obesity, all years — https://data.cdc.gov/resource/hn4x-zwk7.json?locationabbr=MN&question=Percent%20of%20adults%20aged%2018%20years%20and%20older%20who%20have%20obesity&stratificationcategory1=Total&$order=yearstart%20DESC
  3. U.S. Census Bureau — Vintage 2024 State Population Totals and Components of Change — https://www2.census.gov/programs-surveys/popest/datasets/2020-2024/state/totals/NST-EST2024-POPCHG2020-2024.csv
  4. U.S. Census Bureau — State Population Totals: 2020s (methodology) — https://www.census.gov/data/tables/time-series/demo/popest/2020s-state-total.html
  5. MN DHS — MHCP Provider Manual, PA Criteria: Anti-Obesity Medications (live page; bot-gated to automated fetch) — https://mn.gov/dhs/partners-and-providers/policies-procedures/minnesota-health-care-programs/provider/types/rx/pa-criteria/anti-obesity-medications.jsp
  6. Wayback capture of the above, 2026-08-21 — the version actually read for this record — https://web.archive.org/web/20260821021525/https://mn.gov/dhs/partners-and-providers/policies-procedures/minnesota-health-care-programs/provider/types/rx/pa-criteria/anti-obesity-medications.jsp
  7. Wayback capture, 2026-07-18 — still dated "March 2023," brackets the DHS revision date — https://web.archive.org/web/20260718080616/https://mn.gov/dhs/partners-and-providers/policies-procedures/minnesota-health-care-programs/provider/types/rx/pa-criteria/anti-obesity-medications.jsp
  8. KFF — Medicaid Coverage of and Spending on GLP-1s (Jan 16, 2026; national context only) — https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
  9. Minnesota Board of Medical Practice — https://mn.gov/boards/medical-practice/

Last reviewed:

Educational information, not medical advice. Treatment requires evaluation by a licensed physician.